Table 1. Clinical characteristics of the cohort and comparison according to atrial fibrillation diagnosis.
| Phase I AFRICAT n = 100 | Phase II AFRICAT n = 259 | |||||||
|---|---|---|---|---|---|---|---|---|
| All | AF (n = 20) | No AF (n = 80)a | No AF (n = 76)b | All | AF (n = 14) | No AF (n = 245)a | No AF (n = 164)b | |
| Age | 70 (68–73) | 69 (66–71.75) | 70 (68–73)* | 70 (68–73) | 72 (69–74) | 71 (69–75) | 72 (69–74)* | 71 (69–73.75) |
| Sex (% female) | 33 (33%)* | 7 (35%) | 26 (32.5%)* | 24 (31.6%)* | 153 (59.1%)* | 7 (50%) | 146 (59.6%)* | 93 (56.7%)* |
| Alchool | 11 (11%) | 1 (5%) | 10 (12.5%) | 10 (13.2%) | 19 (7.4%) | 0 (0%) | 19 (7.8%) | 12 (7.4%) |
| Tobacco | 20 (20.2%)* | 4 (20%) | 16 (20.3%)* | 15 (20%)* | 23 (8.9%)* | 0 (0%) | 23 (9.4%)* | 17 (10.4%)* |
| Dyslipidaemia | 81 (81%) | 16 (80%) | 65 (81.3%) | 61 (80.3%) | 212 (81.9%) | 10 (71.4%) | 202 (82.4%) | 133 (81.1%) |
| Coronary heart disease | 18 (18%) | 8 (40%)*$ | 10 (12.5%)$ | 10 (13.2%)$ | 49 (18.9%) | 1 (7.1%)* | 48 (19.6%) | 33 (20%) |
| Heart failure | 3 (3%) | 3 (15%)$ | 0 (0%)*$ | 0 (0%)*$ | 23 (8.9%) | 0 (0%) | 23 (9.4%)* | 13 (8%)* |
| Valvular disease | 4 (4%) | 3 (15%)$ | 1 (1.3%)$ | 1 (1.3%)$ | 12 (4.7%) | 1 (7.1%) | 11 (4.5%) | 8 (4.9%) |
| Previous stroke | 6 (6%) | 2 (10%) | 4 (5%) | 2 (2.6%) | 18 (6.9%) | 0 (0%) | 18 (7.3%) | 14 (8.5%) |
| Anticoagulation | 9 (9%)* | 8 (40%)*$ | 1 (1.3%)$ | 1 (1.3%)$ | 2 (0.8%)* | 0 (0%)* | 2 (0.8%) | 1 (0.6%) |
| Antiagregation | 50 (50%) | 7 (35%) | 43 (53.8%) | 40 (52.6%) | 130 (50.2%) | 8 (57.1%) | 122 (49.1%) | 79 (48.2%) |
| SBP | 143.5 (134–153.5) |
140.5 (127.5–162.5) |
144 (134–151.75)* |
144 (134.25–151.75)* |
139 (130.5–147.5) |
143.5 (130.25–152.25) |
138 (130–147)* |
136.5 (130–147)* |
| DBP | 78 (72.25–86) |
79 (73.25–90.75) |
78 (71.25–85.75) |
78 (71.25–86) |
76 (71–83) |
74 (70.75–83.75) |
76 (71–83) |
76 (71.82) |
aPatients without AF included in the devices analysis
bPatients without AF included in the biomarker analysis excluding those without blood samples or short/bad quality registers.
*P-value < 0.05 Phase I vs Phase II comparison
$P-value < 0.05 AF vs no AF comparison.
AF, atrial fibrillation; DBP, diastolic blood pressure; SBP, systolic blood pressure.